Price movement over the last 24 hours
Agilysys Inc vs Johnson & Johnson — how do they compare? Agilysys Inc trades at $105 (market cap $3.18B), while Johnson & Johnson trades at $263.4 (market cap $643.30B). The key difference: Johnson & Johnson is far larger — about 202.3× Agilysys Inc's market cap, and Johnson & Johnson pays a 2.01% dividend while Agilysys Inc pays none. Which is the better fit depends on your goals.
| AGYS | JNJ | |
|---|---|---|
Market Cap | $3.18B | $643.30B |
Sector | Technology | Health |
52-Week High | $141.12 | $267.24 |
52-Week Low | $62.19 | $155.17 |
Enterprise Value | $3.08B | $676.24B |
Volume | — | 6,156,228 |
Dividend Yield | — | 2.01% |
Signals from Pluang's Aura AI — not financial advice
Agilysys (AGYS) trades at $111.00, up 0.17% with strong bullish technical indicators and unanimous analyst support. The stock shows robust fundamentals with 62.61% gross margins and accelerating revenue growth, projected to reach $319 million in 2026. Recent earnings beats and positive guidance highlight the company's momentum in hospitality technology solutions.
The outlook remains positive with 100% buy ratings and a $110 consensus target, though high valuation multiples (P/E 81.05) and overbought RSI levels suggest near-term consolidation risks. Long-term growth drivers include AI integration and subscription revenue expansion, but investors should monitor execution against elevated expectations.
Johnson & Johnson (JNJ) trades at $267.24, up 1.6% today, near its 52-week high. The stock shows strong profitability with a 21.83% net income margin and 26.42% ROE, though valuation ratios like P/E of 30.05 are elevated. Recent earnings have mostly beaten expectations, with Q1 2026 EPS of $2.70 surpassing estimates. Technical indicators are bullish, with the price above key moving averages and support at $256.
JNJ's outlook is supported by steady revenue growth and a robust dividend, but high valuation and debt-to-asset ratio of 24.06% pose risks. Analyst consensus is bullish with a $260 price target, though near-term performance may hinge on Q2 2026 earnings due July 15. Investors should weigh solid fundamentals against premium pricing and macroeconomic pressures.
Trailing returns across standard periods
Latest headlines on both assets
Agilysys provides enterprise software and SaaS solutions for the hospitality industry. Its products specialize in point-of-sale, property management, and inventory systems for hotels, resorts, and cruise lines.
Read more on AGYS →Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →